Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Surmodics Inc.

    NASDAQ: SRDX · Real-Time Price · USD
    29.30
    -0.50 (-1.68%)
    At close: Jun 06, 2025, 3:59 PM
    29.40
    0.34%
    After-hours: Jun 06, 2025, 05:32 PM EDT
    -1.68%
    Bid 28.97
    Market Cap 418.97M
    Revenue (ttm) 121.58M
    Net Income (ttm) -19.86M
    EPS (ttm) -1.4
    PE Ratio (ttm) -20.93
    Forward PE -113.77
    Analyst Hold
    Ask 36.2
    Volume 58,363
    Avg. Volume (20D) 99,555
    Open 29.98
    Previous Close 29.80
    Day's Range 29.10 - 30.01
    52-Week Range 26.00 - 42.44
    Beta 1.32

    About SRDX

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol SRDX
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for SRDX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    1 month ago
    -9.44%
    Surmodics shares are trading lower. The company re... Unlock content with Pro Subscription
    news image

    1 week ago · zacks.com

    Why Is SurModics (SRDX) Up 6% Since Last Earnings Report?

    SurModics (SRDX) reported earnings 30 days ago. What's next for the stock?

    news image

    1 month ago · zacks.com

    SRDX Stock Down Following Q2 Earnings Miss, Gross Margin Contracts

    Despite the strength in Pounce thrombectomy device platforms and strong IVD product sales, Surmodics' second-quarter fiscal 2025 results show weak performance.

    news image

    1 month ago · zacks.com

    SurModics (SRDX) Reports Q2 Earnings: What Key Metrics Have to Say

    The headline numbers for SurModics (SRDX) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estima...

    news image

    1 month ago · zacks.com

    SurModics (SRDX) Reports Q2 Loss, Misses Revenue Estimates

    SurModics (SRDX) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to earnings of $0.07 per share a year ago.

    news image

    1 month ago · businesswire.com

    Surmodics Reports Second Quarter of Fiscal Year 2025 Financial Results; Introduces Fiscal Year 2025 Financial Guidance

    EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial res...

    news image

    1 month ago · businesswire.com

    Surmodics to Report Second Quarter of Fiscal 2025 Financial Results on April 30

    EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that second...

    news image

    1 month ago · businesswire.com

    Surmodics Announces Publication of TRANSCEND Trial, Highlighting Drug-Delivery Technology of its SurVeil™ Drug-Coated Balloon

    EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced the publica...

    news image

    2 months ago · zacks.com

    SRDX Stock Dips Despite the Launch of Pounce XL Thrombectomy System

    Surmodics launches the Pounce XL Thrombectomy System, aiming to enhance clot removal efficiency, improve patient outcomes, and expand its portfolio of vascular interventions.

    news image

    2 months ago · businesswire.com

    Surmodics Announces Commercial Release of Pounce™ XL Thrombectomy System, Enabling Rapid Non-Surgical Clot Removal in Iliac and Femoral Arteries

    EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced the commerc...

    news image

    2 months ago · zacks.com

    Here's Why You Should Retain Surmodics Stock in Your Portfolio Now

    SRDX stock falls more than 26% so far this year. However, this provides a unique opportunity to generate double-digit returns within a couple of months.

    Add to Watchlist